Rapid Rx Quiz: COVID Treatments

Mary L. Windle, PharmD


March 01, 2022

According an analysis of data by the NIH and FDA, as of mid-December 2021, when exposed in laboratory tests to Omicron, sotrovimab and tixagevimab plus cilgavimab (Evusheld) retained their neutralizing activity but casirivimab plus imdevimab (REGN-COV) and bamlanivimab plus etesevimab lost most of their effectiveness.

Learn more about investigational antibody-directed therapies for COVID-19.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.